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Infection with the Epstein-Barr virus (EBV) is often subclinical in the presence of a healthy immune
response; thus, asymptomatic infection is largely uncharacterized. This study analyzed the nature of EBV
infection in 20 asymptomatic immunocompetent hosts over time through the identification of EBV strain
variants in the peripheral blood and oral cavity. A heteroduplex tracking assay specific for the EBV gene LMP1
precisely identified the presence of multiple EBV strains in each subject. The strains present in the peripheral
blood and oral cavity were often completely discordant, indicating the existence of distinct infections, and the
strains present and their relative abundance changed considerably between time points. The possible trans-
mission of strains between the oral cavity and peripheral blood compartments could be tracked within subjects,
suggesting that reactivation in the oral cavity and subsequent reinfection of B lymphocytes that reenter the
periphery contribute to the maintenance of persistence. In addition, distinct virus strains persisted in the oral
cavity over many time points, suggesting an important role for epithelial cells in the maintenance of persis-
tence. Asymptomatic individuals without tonsillar tissue, which is believed to be an important source of virus
for the oral cavity, also exhibited multiple strains and a cyclic pattern of transmission between compartments.
This study revealed that the majority of patients with infectious mononucleosis were infected with multiple
strains of EBV that were also compartmentalized, suggesting that primary infection involves the transmission
of multiple strains. Both the primary and carrier states of infection with EBV are more complex than previously
thought.
Epstein-Barr virus (EBV) is a human herpesvirus that es-
tablishes a life-long persistent infection in more than 90% of
the world’s population. Primary infection with the virus is usu-
ally asymptomatic but can result in the self-limiting disease
infectious mononucleosis. EBV is associated with numerous
pathologies that develop in B lymphocytes and epithelial cells,
including Burkitt’s lymphoma, Hodgkin’s disease, AIDS-asso-
ciated and posttransplant lymphomas, nasopharyngeal carci-
noma, hairy leukoplakia, and several others (21).
EBV persists in memory B lymphocytes, which may expand
in response to their cognate antigen and subsequently differ-
entiate into plasma cells, in which viral reactivation and repli-
cation may occur (1, 2). The role of EBV replication in the
maintenance of persistent infection is not well characterized.
Viral proteins indicative of replication have been detected in
lymphocytes in the tonsillar tissue, and replicating virus has
been detected in sloughed oropharyngeal epithelial cells (1, 14,
17, 23, 29). The replication and subsequent release of virus into
the oral cavity permit transmission of the virus to a new host
and possibly reinfection of oropharyngeal epithelial cells and B
lymphocytes. The virus detected in the oropharynx is thought
to be released from epithelial cells or lymphocytes trafficking
near mucosal surfaces; however, several studies have suggested
that the prevalent viruses in the oral cavity and peripheral
blood may be different (5, 22).
Several variants of EBV have been identified by polymor-
phisms in the viral genome. EBV types 1 and 2 are distin-
guished by sequence changes in EBV nuclear antigens 2 and 3
(EBNA2 and -3). Strain-specific changes have also been iden-
tified in EBNA1, BZLF1, and LMP1. LMP1 is quite variable,
and seven phylogenetically distinct strains of LMP1 have been
described that have signature changes in the coding sequence
(6). Individual isolates differ by these specific base pair chang-
es: the presence or absence of a 30-bp deletion, the number of
33-bp repeats, and a 15-bp insertion within one of the repeats
(15). Based on these consistent sequence variations, a hetero-
duplex tracking assay (HTA) has been developed that analyzes
a 264-bp region within the carboxy terminus of LMP1 and can
distinguish each of the LMP1 variants (22).
In immunosuppressed individuals, infection with multiple
strains and types of EBV is a frequent occurrence, and both
types of EBV and multiple strains have been identified in the
permissive lesion hairy leukoplakia (18, 22, 30). A single study
that used markers such as the number of repeated sequence
elements, restriction enzyme polymorphisms, or the presence
or absence of the 30-bp deletion has shown that immunocom-
petent individuals may also harbor at least two strains (24).
Infection with multiple strains may indicate that even a healthy
individual’s immune response is not sufficient to protect
against secondary infections with additional EBV strains. Al-
ternatively, individuals may be initially infected with multiple
EBV strains. A recent study showed that in immunosuppressed
individuals, the number and relative abundance of EBV strains
changed over time (22).
In the current study, the EBV strains present in the oral
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cavity and peripheral blood were identified in healthy, asymp-
tomatic carriers at multiple time points. The data revealed that
most individuals harbor multiple EBV variants and that the
relative abundance and presence of the strains differ over time.
The prevalent EBV strain in the oral cavity was usually distinct
from that in the peripheral blood; however, in most cases, all
strains were eventually detected in the saliva and blood, sug-
gesting transmission between the compartments.
MATERIALS AND METHODS
Patient samples. Blood was collected from 20 asymptomatic EBV-positive
carriers by a finger prick. Subjects ranged in age from 8 to 50 years old. Blood was
collected by routine venipuncture from infectious mononucleosis patients, and
lymphocytes were separated by a Ficoll step gradient. Throat wash samples were
obtained by having subjects gargle with 5 ml of sterile phosphate-buffered saline.
Nucleic acid isolation. DNA was purified from lymphocytes with the DNeasy
tissue kit (Qiagen, Valencia, Calif.). DNA was harvested from 200 l of whole
blood or throat wash sample with the High Pure viral nucleic acid isolation kit
(Roche Molecular Biochemicals, Indianapolis, Ind.).
Amplification of LMP1. LMP1 was amplified from patient samples by nested
PCR with 300 ng of DNA template in duplicate independent reactions. The
reaction mixture contained 1 U of Taq DNA polymerase (Promega, Madison,
Wis.); a 1:10 dilution of reaction buffer; a final concentration of 2.0 mM MgCl2;
a final concentration of 10 mM each of a mix containing dATP, dGTP, dCTP,
and dTTP (Promega); and 25 pmol of each primer in a 50-l reaction volume.
The first round of amplification with primers LMP-3UT, EBV genome coordi-
nates 168017 to 168036 (ATCACGAGGAATTCAATGTGGCTTTTCAGCCT
AG) (6) and FUC-HIND3, EBV genome coordinates 168427 to 168408 (ATC
AGAGAGCTTTGACAATGGCCCACATGACC) (22) yielded a 411- or 381-bp
product, depending on the presence or absence of a 30-bp deletion.
The second round of PCR with 6 l of template from the first reaction was
performed with primers FUE-ECO, EBV genome coordinates 168163 to 168183
(ATCACGAGGAATTCGTCATAGTAGCTTAGCTGAAC) (15) and FUC-
HIND3, which yielded a 264- or 234-bp product.
The strain controls for the HTA were amplified from 200 ng of cloned DNA
in one round of PCR with primers FUE-ECO and FUC-HIND3. Amplification
was performed in a Robocycler Gradient 96 (Stratagene, La Jolla, Calif.) for 30
to 35 cycles for each round of PCR (1 min each of denaturation at 95°C,
annealing at 55°C, and extension at 72°C). PCR products were analyzed by 1.5%
agarose gel electrophoresis and visualized by ethidium bromide staining.
HTA. The phylogenetically distinct LMP1 variants that have been identified
include the prototypic undeleted strain B958, other undeleted strains (Ch2, AL,
NC, and Med), and strains with the 30-bp deletion (Med and Ch1) (6).
Variants were previously named for the origin of the patient sample from which
they were first isolated, but they are not restricted to that geographical region.
The Ch1 and Ch2 strains were originally identified from Chinese nasopharyngeal
carcinoma specimens, the AL strain was from an Alaskan case of nasopharyngeal
carcinoma, and the Med strains were first identified in nasopharyngeal carci-
noma specimens from the Mediterranean (6, 15, 26). The NC strain was origi-
nally identified in an infectious mononucleosis patient in North Carolina (6).
Clones of the carboxy terminus were prepared from each variant and used as
positive controls for the HTA to determine the migration position of each
variant. Each patient sample was analyzed with a probe of the undeleted Ch2
variant and the deleted Med variant to precisely identify the strains present.
Ch2 and Med strain-specific probes were made as previously described (22).
Briefly, clones of Ch2 and Med (EBV coordinates 168163 to 168427) were
digested with EcoRI (New England Biolabs, Beverly, Mass.) to linearize the
vector. The plasmid was end labeled for 30 min at room temperature in a
reaction volume of 30 l containing 25 Ci of [35S]dATP. The linearized vector
was digested with HindIII (New England Biolabs) to release the radiolabeled
fragment from the vector.
The heteroduplex formation reaction was performed with 8 l of PCR product
of a strain control or a patient sample, 1 l of annealing buffer (1 M NaCl, 100
mM Tris-HCl [pH 7.5], 20 mM EDTA), and 1 l of radiolabeled probe. The
mixtures were denatured for 5 min at 100°C and allowed to reanneal for 4 min
at 4°C. The reactions were separated in nondenaturing 10% polyacrylamide gels
(Hoefer apparatus; Pharmacia Biotech, San Francisco, Calif.) and subsequently
dried in a gel drier (Bio-Rad, Hercules, Calif.) and exposed to a Phosphorimager
(Molecular Dynamics, Sunnyvale, Calif.).
Sequence analysis. Sequence analysis was performed on a subset of samples to
confirm the results of the HTA. From those samples that displayed a band with
a consistent, unique migration, sequence analysis was performed on the sample
that predominantly contained the strain of interest with the primer FUE-ECO.
The samples were sequenced at the University of North Carolina-Chapel Hill
Automated DNA Sequencing Facility on a model 3100 genetic analyzer (Applied
Biosystems Division, Perkin-Elmer Cetus, Norwalk, Conn.) with the ABI Prism
Dye Terminator cycle sequencing ready reaction kit with AmpliTaq DNA poly-
merase FS (Applied Biosystems Division, Perkin-Elmer Cetus).
RESULTS
EBV strain profiles of asymptomatic carriers. To identify
and determine the relative abundance of the EBV strains
present in blood and saliva, DNA was extracted from throat
wash samples and total blood samples at multiple time points
from 20 asymptomatic individuals and analyzed for the pres-
ence of LMP1 variants with the LMP1-HTA. HTA analysis is
based on the principle that completely homologous DNA mol-
ecules (homoduplexes) migrate according to size in a poly-
acrylamide gel, whereas heteroduplexes with base pair differ-
ences will migrate more slowly due to malformations in the
DNA helix. Seven phylogenetically distinct forms of LMP1
have been identified by their sequence differences and signa-
ture amino acid changes. These include the prototypic unde-
leted strain B958, other undeleted strains (Ch2, AL, NC, and
Med), and strains with the 30-bp deletion (Med and Ch1).
The LMP1-HTA could distinguish each of the LMP1 vari-
ants based on a consistent migration pattern when heterodu-
plexed to the Ch2 and Med probes (Fig. 1). In some of the
patient samples, a few bands appeared as doublets, and some
background bands were visible. These additional bands were
presumed to be aberrantly migrating heteroduplexes, charac-
teristic of the probe, as they were not present in analyses with
both probes. Other samples contained bands with slight alter-
ations in migration. These bands were shown to reflect variants
that were detected with both probes and shown to have addi-
tional base pair changes from the known control strain se-
quences by sequence analyses (Fig. 2, throat wash sample day
112).
The LMP1-HTA has been previously shown to identify vari-
ants present in 1% of a mixed population (22). In order to
determine the detection capabilities in a background of nega-
tive lymphocytes, EBV-negative DG75 cells were mixed with
EBV-positive Raji cells, which contain 50 copies of the EBV
episome per cell. The PCR conditions and the LMP1-HTA
could easily detect one Raji cell in a background of 1.5  106
DG75 cells (data not shown).
A time course of samples that were collected during a 10-
month period and analyzed by the LMP1-HTA (Med probe)
is presented for subject N11 (Fig. 2). Each patient sample was
also analyzed with the Ch2 probe to differentiate between the
Med and NC strains and the AL and Ch2 strains, which
migrate to a similar position with the Med probe (data not
shown). A blood sample was not available at day 112. At the
first time point, strains detected in the peripheral blood in-
cluded Med, AL, and Med, while strains in the oral cavity
included AL, Med, and B958. The Med strain was not
present in the throat wash sample on day 1 and was not de-
tected in either compartment on day 22. However, on day 42,
it appeared in the oral cavity but not in the blood. At the next
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collection, at day 73, it was present in the blood but not the
throat wash sample and then was not detectable on days 112,
258, and 284.
The absence of Med in the blood between time points may
indicate that the infected cells carrying this strain had entered
secondary lymphoid organs and were temporarily undetectable
in the blood (13). The AL strain persisted in both the periph-
eral blood and oral cavity and was detected in each compart-
ment at the majority of time points analyzed.
The B958 strain was detected only in the oral cavity at day 1,
then only in the blood at day 22, and was not detectable in
either compartment on day 42. B958 reappeared in the oral
cavity at day 73 and was subsequently detected in the blood at
the next time points tested, days 258 and 284. It is interesting
that the appearance of B958 in the blood corresponded with an
earlier detection of the strain in the oral cavity, similar to the
pattern observed for Med. A distinct variant of B958 marked
by an additional base pair change (266A3T) was detected in
the oral cavity at day 112, where it persisted for 5 months. The
continued detection of this specific variant only in the oral
cavity may indicate that EBV strains persist in oropharyngeal
epithelial cells in a chronic lytic infection. The Med strain
also exhibited a variable profile that increased and decreased
in relative abundance in each compartment over time. The Ch1
strain was detected in the oral cavity at the final time point but
was not detected in any of the previous samples.
FIG. 1. Migration position of LMP1 variants heteroduplexed to an undeleted and deleted probe. Only the regions of the gel that contained the
heteroduplexes are shown. Undeleted strains bound to an undeleted probe migrate low in the gel, while deleted strains migrated high in the gel
because of the large malformation of the DNA helix. In contrast, deleted strains bound to a deleted probe migrated more according to size due
to relatively little mismatch, while undeleted strains migrated high in the gel. PCR-amplified control strains B958, Ch2, AL, NC, Med, and Med
were denatured with and reannealed to (A) the undeleted Ch2 probe and (B) the deleted Med probe.
FIG. 2. Strain profile of asymptomatic EBV carrier N11 determined by LMP1-HTA with the Med probe. Peripheral blood (P) and throat
wash (T) samples were collected over 284 days. On day 112, a blood sample was not available. Strains were identified based on their migration in
relation to that of known strain controls.
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A striking dynamic strain profile was also detected in subject
N5 (Fig. 3). Analyses of this subject revealed an actively chang-
ing strain profile where strains appeared, disappeared, and
reappeared. Furthermore, strains appeared to be transmitted
between compartments. Several strains, including NC, B958,
and Med, persisted over multiple time points. Samples were
collected from this subject over 10 months; a blood sample was
not available at day 19, and a throat wash sample was not
available at day 61. At day 1, the NC strain was the only strain
detected in the peripheral blood, while strains detected in the
throat wash sample included NC, Ch1, Med, and trace
amounts of B958 and Ch2. At day 19, only a B958 variant
(266A3T) was present in the throat wash sample. The strain
profile in both compartments continued to change dramatically
throughout the time course. At day 41, five strains were de-
tected in the blood that were the same strains detected in the
oral cavity at day 1, while the throat wash sample at day 41
predominantly contained Ch1 with trace levels of Med, B958,
and Ch2.
The blood sample at day 61 looked identical to the throat
wash sample from day 41 with the notable absence of the NC
strain. The NC strain reappeared and was abundant in both
samples on days 92 and 126, but then disappeared and was not
detectable on days 286 and 312. The blood sample from day
126 with abundant NC and trace levels of Med was nearly
identical to the profile in the blood at day 1. The throat wash
sample at day 126 contained NC, Ch2, B958, and Med. These
strains, Ch2, B958, and Med, were subsequently detected in
the blood, as indicated by the strain profile at day 286 and the
final time point on 312. This may indicate that the peripheral
blood lymphocytes have been infected with virus from the oral
cavity. The cycling of strains between the oral cavity and pe-
ripheral blood reveals that virus may continuously traffic be-
tween compartments, which may be an important part of the
virus life cycle.
Similar analyses of each of the 20 subjects in this study
revealed that all subjects were infected with multiple strains.
Infection with two to three EBV strains was detected in six
subjects, four strains in eight subjects, and five to six strains in
six subjects. The strain profiles of each subject frequently var-
ied at individual time points, but some strains persisted at
multiple time points. Clear compartmental differences be-
tween the oral cavity and peripheral blood were detected at
individual time points in 16 of the 20 subjects. The predomi-
nance of a strain in one compartment and its absence in the
other compartment likely reflect the limits of detection but
also indicate clear differences in relative abundance in the two
compartments.
The detection of unique strains in the oral cavity before their
detection in the blood may represent the acquisition of a new
strain from an exogenous source. Alternatively, unique strains
in the oral cavity may represent virus produced by plasma cells
in the oral lymphoid tissue that underwent selection and mat-
uration upon stimulation with their cognate antigen. Viral
DNA detected in the peripheral blood likely represents intra-
cellular EBV from infected memory B lymphocytes and pos-
sibly cell-free viral DNA released from lymphocytes that have
died due to immune surveillance.
At each collection, subjects completed a questionnaire re-
garding their perceived level of stress, any symptoms of ill
health, including fatigue, sore throat, and runny nose, and if
they had previously been diagnosed with infectious mononu-
cleosis. Regardless of sickness or stress level, EBV was de-
tected at each time point in both the oral cavity and peripheral
blood. The strain profiles did not differ between subjects who
had and had not experienced infectious mononucleosis. These
FIG. 3. Strain profile of asymptomatic EBV carrier N5 determined by LMP1-HTA with the Med probe. Peripheral blood (P) and throat wash
(T) samples were collected over 312 days. On day 19, a blood sample was not available, and on day 61, a throat wash sample was not collected.
Strains were identified based on their migration in relation to that of known strain controls.
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analyses suggest that EBV infection involves the active ex-
change of virus between the peripheral blood and the oral
cavity, where distinct virus strains increased and decreased in
relative abundance and appeared to cycle between compart-
ments.
EBV strain profiles of asymptomatic atonsillar carriers.
EBV is believed to persist in a latent infection in memory B
cells, which may reactivate at mucosal surfaces. Viral replica-
tive antigens have been detected in reactivated tonsillar lym-
phocytes. To determine if the absence of tonsillar tissue af-
fected the presence of EBV or the strain profiles in the oral
cavity, analyses of the asymptomatic EBV carriers included six
subjects whose palatine tonsils and/or adenoids had been sur-
gically removed at least 10 years prior to this study. The data
indicate that subjects who had their palatine tonsils removed
did not differ from other asymptomatic carriers with regard to
the number of strains, compartmentalization, and transmission
between compartments. However, these individuals retained
other lymphoid tissues, including the tubal and lingual tonsils.
In addition, regrowth of palatine tonsils may occur.
Subject A6 underwent a tonsillectomy that also included the
removal of adenoidal tissue 20 years prior to enrollment in this
study. Samples were collected over 11 months and analyzed by
LMP1-HTA (Fig. 4). At day 1, NC was strikingly abundant in
the blood, with trace levels of Ch2 and a B958 strain with a
distinct migration pattern. Only this B958 strain, marked by a
base pair change at position 266A3T, was detected in the
throat wash sample at day 1, and it was subsequently the only
strain detected in the blood on day 168. It was not detected in
the blood or throat wash sample on day 194, but then reap-
peared in both compartments at day 314. The NC strain that
was the prevalent strain in the blood at day 1 was not detected
in the blood on day 168 but was present in the oral cavity. It
was not detected in either sample on day 194 but reappeared
in the blood on day 314. The throat wash sample on day 168
contained both NC and the distinct B958 and also contained
Ch2 and Med, which were detected for the first time. Ch2
and Med were both subsequently detected in the blood at
day 194. The strains in the oral cavity and peripheral blood of
this atonsillar subject were consistently different from each
other at each time point. At day 314, Ch2 was present in the
blood but not the throat wash sample, while Med was de-
tected in the throat wash sample but not the blood.
The AL and Ch1 strains were detected in the blood only at
day 194, while a B958 strain, without the additional base pair
change, was detected at high levels only in the oral cavity.
These three strains were not subsequently detected at day 314.
Analyses of infectious mononucleosis subjects. The com-
plexity of EBV infection in immunocompetent asymptomatic
carriers was unexpected. Whether individuals are subject to
repeated infections throughout life or the immune response to
EBV protects against secondary infections with similar and/or
different strains is unknown. Because EBV is transmitted
through saliva, the presence of multiple strains in throat wash
samples suggested that multiple strains might be transmitted
during primary infection. In order to investigate the number of
strains acquired in the course of infectious mononucleosis,
blood and throat wash samples were collected from 15 subjects
on the day of diagnosis. These analyses revealed that 13 of 15
subjects were infected with multiple EBV strains, and each of
the 13 subjects had compartmental differences in strain profiles
(Table 1, Fig. 5). Four of 13 subjects were infected with two
strains, a single different strain in each compartment, which
may indicate that the virus unique to the oral cavity was more
efficient at lytic replication and less efficient at establishing a
latent infection in B lymphocytes. The peripheral blood of 5 of
13 subjects and the oral cavity of 6 of 13 subjects contained two
or more strains, demonstrating that multiple strains can estab-
lish an infection in both compartments upon primary infection.
Subjects MO1 and MO2 both contained a single deleted
strain in both compartments (Fig. 5). In the blood and throat
wash samples of MO1, Med was detected, and in subject
MO2, Ch1 was detected. The blood of MO3 contained Ch2,
while the throat wash sample had B958 and possibly several
unique forms (Fig. 5). The blood of MO4 contained only Ch2,
with both Ch2 and Med detected in the throat wash sample
(Fig. 5). Ch2 was the most abundant strain in the blood of
MO5, with trace amounts of B958 and a distinct Ch1 strain.
FIG. 4. Strain profile of asymptomatic atonsillar EBV carrier A6
determined by LMP1-HTA with the Med probe. Peripheral blood
(P) and throat wash (T) samples were collected over 314 days. Strains
were identified based on their migration in relation to that of known
strain controls.






MO3 Ch2 B958 (266 A 3 T)
MO4 Ch2 Ch2, Med
MO5 Ch2 Ch2, Med, B958 (266 A 3 T)
MO6 B958 Ch1, NC, Med, B958




MO11 Ch2, Med Med
MO12 Ch1, B958 Ch1, Med
MO13 Ch1, Ch2 Ch1
MO14 Ch2, NC NC
MO15 Ch2, Med, B958 B958, Med
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The throat wash sample contained the same strains at different
relative levels compared to the blood; B958 and the distinct
Ch1 were the most abundant, with a decreased level of Ch2
(Fig. 5).
DISCUSSION
The identification of strain variants is an effective approach
to investigating virus transmission and persistence. EBV types
can be identified by sequence divergence in the EBNA2 and
EBNA3 genes. Another method of distinction called Ebnotyp-
ing distinguishes strains based on the size pattern of EBNA1,
EBNA2, and EBNA3A, -3B, and -3C, which all contain repeat
elements resulting in slightly different protein sizes. Ebnotyp-
ing has been used to study the transmission of virus within
families (8). LMP1 is the most discriminating locus for EBV
genotyping and has been widely used to identify strain variants
by the presence or absence of a 30-bp deletion in the carboxy
terminus.
In order to identify precisely the five undeleted and two
deleted LMP1 strains, specific base pair changes in addition to
the deletion must be considered. It is likely that numerous
substrains exist that have additional base pair changes in ad-
dition to the sequence changes in the known strains, as dem-
onstrated in this study by the identification of a B958 strain
with an additional change at position 266. Previous studies
have used cloning and sequencing to identify multiple LMP1
strains in tissue and blood samples (31). The LMP1 HTA
enables the identification of all strain variants and reveals their
relative abundance. This analysis allows accurate studies of
transmission and persistence of the EBV strains represented
by the LMP1 variants (22).
The presence of multiple strains in immunocompromised
patients has been well described (3, 22, 34). The immune
response generated during primary infection was thought to be
effective in the prevention of subsequent superinfection with
new viruses, while a weakened immune system was originally
believed to be responsible for the susceptibility to superinfec-
tion with additional EBV strains. This is the first longitudinal
study to characterize the changing nature of infection in the
blood and oral cavity in human immunodeficiency virus-nega-
tive immunocompetent subjects. This study reveals that infec-
tion with EBV in the presence of a healthy immune response
involves multiple strains with clear differences in relative abun-
dance between the blood and oral cavity at a given time point.
Although different strain profiles were detected at each time
point, the strains demonstrated a corresponding rise and fall in
relative abundance over time. For example, if a new strain was
detected in the blood, it was often paralleled by a simultaneous
decrease in abundance of another strain, which likely reflects a
steady level of infected cells. The number of resting B lympho-
cytes infected with EBV has been reported to be relatively
stable, ranging from 1 to 50 per 106 B cells; however, the life
span of each infected cell is unknown (11). Memory B lym-
phocytes are the main cell type involved in persistent EBV
infection; therefore, the maintenance of persistent EBV infec-
tion depends on the survival of an infected memory B cell or
the continual reinfection of new cells that reseed the memory
cell population.
The abundance of EBV-specific CD8 T lymphocytes to
viral proteins expressed in proliferating, latently infected lym-
phocytes suggests that expression of these proteins and B-cell
proliferation may be common (12, 16). In addition, studies
have revealed that in immunocompetent individuals, the T-cell
response to lytic cycle antigens was more predominant than the
responses to latent antigens, suggesting that reactivation to
replication also occurs constantly (25, 28). In the tonsillar tis-
sue in the oral cavity, reactivated lymphocytes undergoing viral
replication have been detected. The subsequent release of vi-
rus into the oral cavity may allow infection of naïve B lympho-
cytes and epithelial cells at mucosal sites (2). Reactivated B
lymphocytes that release virus into the oral cavity would die
due to lytic viral replication; therefore, the persistent detection
of specific strains in the oral cavity over time suggests that a
chronic replicative phase may occur in epithelial cells. Thus,
the oral cavity may be a temporary reservoir of virus for de
novo infection of naive B lymphocytes. The two compartments
are clearly related, since the strains were not restricted to one
compartment, but the strains appeared to cycle in relative
abundance between the oral cavity and peripheral blood. The
variation in relative abundance of a given strain within the
peripheral blood may indicate that the infected lymphocytes
may enter secondary lymphoid tissue that was not sampled in
this study.
The potential alternating infection of B lymphocytes and
epithelial cells is conceivably an important component in the
viral life cycle (4). A recent study has shown that the glyco-
proteins present in the virion envelope determine infection of
the two cell types. Entry of EBV into B lymphocytes requires
a tripartite glycoprotein complex containing gH, gL, and gp42,
while entry into an epithelial cell requires a bipartite complex
composed of gH and gL (32). The virus released from a B
lymphocyte has less gp42 and therefore has a decreased effi-
ciency for infection of B lymphocytes and an increased ability
for infection of epithelial cells (4). Virus released from epithe-
lial cells contains relatively more gp42 and can efficiently infect
FIG. 5. Strain profiles of five different infectious mononucleosis
patients (MO1 to MO5) determined by LMP1-HTA with the Med
probe. Peripheral blood (P) and throat wash (T) samples were col-
lected at the day of diagnosis. Strains were identified based on their
migration in relation to that of known strain controls.
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B lymphocytes (4). The regular cycling of virus between the
oral cavity and peripheral blood in asymptomatic carriers sug-
gests that this process occurs in vivo. In addition, the persis-
tence of distinct strains in the oral cavity implicates the epi-
thelial cell reservoir in the maintenance of persistent infection
and in transmission to subsequent hosts.
The majority of EBV-infected B lymphocytes are detected in
the peripheral circulation and in the oropharyngeal lymphoid
tissues, specifically, the tonsils and adenoids that constitute
Waldeyer’s ring (13). Our investigation of asymptomatic car-
riers included analyses of subjects that had undergone tonsil-
lectomies and/or adenoidectomies between childhood and ad-
olescence. These subjects also exhibited multistrain profiles
that appeared to cycle between compartments, similar to those
of subjects who retained their tonsils and adenoids. The de-
tection and persistence of distinct strains in the oral cavity in
these subjects also suggests chronic infection at some oral site.
Tonsillectomies involve removal of the lymphoid-rich palatine
tonsils; however, the remaining tonsillar tissue may also harbor
infected B lymphocytes that release virus into the oral cavity. It
is also likely that replication in parotid epithelial cells is an
important source of virus in the oral cavity and participates in
the exchange of virus between compartments (33).
This study reveals for the first time that primary infection
during infectious mononucleosis can involve multiple EBV
strains. This is not surprising, based on the data presented in
this study, which revealed multiple strains in the saliva of
asymptomatic carriers, which presumably would be the inocu-
lum to infect another person. The presence of multiple strains
at primary infection has also been described for other viruses,
including human immunodeficiency virus and human herpes-
virus 6 (10, 20).
The majority of mononucleosis cases (13 of 15) also exhib-
ited compartmentalization of strains between the blood and
oral cavity. As the symptoms of infectious mononucleosis be-
come apparent 4 to 8 weeks after exposure to EBV, viral
dissemination and transmission between compartments has
likely already occurred (19, 27). Therefore, it is quite striking
that in 10 of 13 subjects, unique strains were detected in the
oral cavity that were not detected in the blood, and the other
three subjects (MO11, MO13, and MO14) contained unique
strains in the blood that were not detected in the oral cavity.
The compartmentalization of strains is similar to the infection
of asymptomatic carriers described in this study. It will be
important to follow patients after primary infection to deter-
mine if multiple strains persist and determine if any strains are
unable to establish a persistent infection in the peripheral
blood or oral cavity. In addition, longitudinal studies will assess
the protective capacity of the immune response generated at
primary infection by determining if new strains are subse-
quently acquired and transmitted to the blood.
The dramatically changing nature of infection in asymptom-
atic carriers has broad implications. Several studies have de-
scribed compartmentalization of EBV variants in tumor tissues
that are distinct from those in the blood at a particular time
point (7, 9). The disappearance and reappearance of strains in
asymptomatic carriers emphasize the importance of analyzing
samples obtained from an individual at multiple time points
before concluding that a particular variant is present or absent.
This study also points to important considerations for future
vaccine development. The continued release of virus into the
oral cavity indicates that the high levels of cytotoxic lympho-
cytes directed against replicative proteins do not prevent virus
replication. In addition, the cycling of strains from the oral
cavity to the peripheral blood may indicate that B lymphocytes
are consistently being reinfected in the oral cavity and then
trafficking into the periphery. This would suggest that the nat-
ural mucosal immune response is not sufficient to protect an
immunocompetent individual from repeated infections with
the same or different strains.
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